Drug Profile


Alternative Names: 1223249; GSK1223249

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Nogo protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis

Most Recent Events

  • 01 Jan 2015 GlaxoSmithKline completed a phase II trial in Amyotrophic lateral sclerosis in USA, Australia, Belgium, Canada, France, Germany, Italy, Japan, South Korea and Netherlands and United Kingdom (NCT01753076)
  • 13 Feb 2014 GlaxoSmithKline completes enrolment in its phase II trial for Amyotrophic lateral sclerosis in USA, Canada, European Union, Australia, Japan & South Korea (NCT01753076)
  • 31 Dec 2013 Phase-II clinical trials in Amyotrophic lateral sclerosis in USA, Japan & South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top